StemCell Therapy

According to results of a study presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting 2019 in National Harbor, Maryland, a next-generation sequencing (NGS)-based approach was capable of simultaneously characterizing all 7 T- and B-cell receptor chains, and also provided potential predictors of treatment benefit in patients with renal cell carcinoma (RCC).

An extensive repertoire of T-celland B-cell populations that expresses a wide range of antigen-specificreceptors are at the heart of the adaptive immune system. More specifically, T-and B-cell receptor diversity is created through random recombination ofvariable (V), diversity (D), and joining (J) gene segments, or V and J genesegments alone. Hence, at any given point in time, the T-cell and B-cellrepertoire in a single individual is represented by a huge number of differentT- and B-cell clones or clonotypes.

Recently, high-throughput NGS hasbeen used to profile the diversity of the T-cell and B-cell repertoire inindividuals. One approach to this process involves RNA-based multiplexpolymerase chain reaction (PCR) amplification of V-D-J or V-J gene segments,followed by high-throughput sequencing of the PCR amplicons, and subsequentbioinformatic interpretation of the reads obtained through NGS.

In thisstudy, a novel quantitative PCR-based NGS technique was reported to allow forthe simultaneous characterization of RNA associated with the loci of all 7 T-and B-cell receptors (ie, the alpha, beta, gamma, and delta chains of theT-cell receptor; and immunoglobulin (Ig)-K and Ig-L of the B-cell receptor)collected from both peripheral blood mononuclear cells (PBMCs) andformalin-fixed paraffin-embedded (FFPE) specimens from patients undergoingtreatment for RCC.

Furthermore,this process was carried out as single reaction that circumvented the problemof PCR dimer artifacts.

Results of this study suggestedthat pretreatment diversity in T-cell receptor alpha and beta chains, as wellas the B-cell to T-cell expression ratio, may be useful predictors of treatmentresponse in patients with RCC.

Reference

Depinet M, Pan W, Wu S, et al. All-in-One, quantitative immune repertoire profiling of PBMC and FFPE for renal cancer treatment evaluation. Presented at the Society for Immunology of Cancer (SITC) Annual Meeting 2019. November 6-10, 2019. National Harbor, MD. Abstract P87.

Read the rest here:
High-Throughput Multichain Immune Repertoire Sequencing for Prediction of Treatment Response in Renal Cell Carcinoma - Cancer Therapy Advisor

This entry was posted on November 18, 2019 at 4:48 am and is filed under Immune System. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |